Short Interest in ENDRA Life Sciences Inc. (NASDAQ:NDRA) Drops By 25.3%

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 58,311 shares, a decline of 25.3% from the December 15th total of 78,064 shares. Based on an average daily volume of 18,189 shares, the short-interest ratio is currently 3.2 days. Currently, 8.6% of the shares of the company are short sold. Currently, 8.6% of the shares of the company are short sold. Based on an average daily volume of 18,189 shares, the short-interest ratio is currently 3.2 days.

ENDRA Life Sciences Stock Performance

Shares of NASDAQ NDRA traded up $0.31 during midday trading on Friday, reaching $4.78. The stock had a trading volume of 11,041 shares, compared to its average volume of 14,628. The stock has a 50-day moving average of $5.32 and a 200-day moving average of $5.39. ENDRA Life Sciences has a 12-month low of $2.90 and a 12-month high of $11.96.

ENDRA Life Sciences (NASDAQ:NDRA) last released its earnings results on Friday, November 14th. The company reported ($1.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.95) by $0.20. Equities analysts anticipate that ENDRA Life Sciences will post -47.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

NDRA has been the topic of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Wednesday, October 8th. Wall Street Zen raised ENDRA Life Sciences to a “sell” rating in a report on Saturday, November 22nd. Finally, Ascendiant Capital Markets cut their price target on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, December 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.